2017
Journal of Health Inequalities, (2017).3 2 10.5114/jhi.2017.74213.
2017
Vaccine, (2017).35 32 10.1016/j.vaccine.2017.06.028.
2017
Vaccine, (2017).37 50 10.1016/j.vaccine.2017.09.083.
SAFETY AND IMMUNOGENICITY OF MONOVALENT AD26. ZEBOV AND MULTIVALENT MVA-BN-FILO HETEROLOGOUS PRIME-BOOST VACCINE REGIMENS AGAINST EBOLA IN AFRICAN HEALTHY ADULT VOLUNTEERS.
2017
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, (2017).97 5
2017
Vaccine, (2017).35 32 10.1016/j.vaccine.2017.05.087.
2017
The Lancet infectious diseases, (2017).17 12 10.1016/S1473-3099(17)30541-8.
2017
BMC public health, (2017).17 1 10.1186/s12889-017-4473-7.
2017
Practice Nursing, (2017).28 10 10.12968/pnur.2017.28.10.413.
2017
Papillomavirus research (Amsterdam, Netherlands), (2017).4, 10.1016/j.pvr.2017.06.003.
2017
Clinical & translational immunology, (2017).6 10 10.1038/cti.2017.46.